Typical antipsychotics

Last updated: February 27, 2023

Typical antipsychotics

Critical Care - Nursing

Critical Care - Nursing

Shock: Clinical
Burns: Clinical
Asthma: Clinical
Seizures: Clinical
Skin cancer: Clinical
Neck trauma: Clinical
Stroke: Clinical
Pancreatitis: Clinical
Heart failure: Clinical
Hypertension: Clinical
Brain herniation
Concussion and traumatic brain injury
Traumatic brain injury: Pathology review
Traumatic brain injury: Clinical
Intracerebral hemorrhage
Bundle branch block
ECG basics
ECG rate and rhythm
ECG axis
ECG cardiac infarction and ischemia
Wolff-Parkinson-White syndrome
Atrioventricular block
Atrioventricular nodal reentrant tachycardia (AVNRT)
Atrial flutter
Atrial fibrillation
ECG normal sinus rhythm
Ventricular arrhythmias: Pathology review
Supraventricular arrhythmias: Pathology review
Ventricular fibrillation
Myocarditis
Class II antiarrhythmics: Beta blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Tricyclic antidepressants
Dilated cardiomyopathy
Class III antiarrhythmics: Potassium channel blockers
Positive inotropic medications
Class I antiarrhythmics: Sodium channel blockers
Coronary artery disease: Pathology review
Seizures: Pathology review
Endocarditis: Pathology review
Shock: Pathology review
Hypertension: Pathology review
Heart failure: Pathology review
Cardiomyopathies: Pathology review
Cirrhosis: Pathology review
Pancreatitis: Pathology review
Headaches: Pathology review
Ventilation-perfusion ratios and V/Q mismatch
Clinical Skills: Mechanical ventilation - conventional ventilators
Clinical Skills: High-frequency oscillatory ventilation (HFOV)
Respiratory alkalosis
Respiratory acidosis
Acute respiratory distress syndrome: Clinical
Pulmonary embolism
Acute respiratory distress syndrome
Advanced cardiac life support (ACLS): Clinical
Deep vein thrombosis and pulmonary embolism: Pathology review
Obstructive lung diseases: Pathology review
Respiratory distress syndrome: Pathology review
Blood products and transfusion: Clinical
Ventilation
Anatomic and physiologic dead space
B- and T-cell memory
Zones of pulmonary blood flow
Action potentials in pacemaker cells
Reading a chest X-ray
Renal failure: Pathology review
Regulation of renal blood flow
Heart failure
Toxidromes: Clinical
Child abuse: Clinical
Carbon monoxide poisoning: Nursing process (ADPIE)
Chest trauma: Clinical
Angina pectoris
Coronary artery disease: Clinical
Antiplatelet medications
cGMP mediated smooth muscle vasodilators
Sympathomimetics: Direct agonists
Compliance of lungs and chest wall
Combined pressure-volume curves for the lung and chest wall
Stable angina
Ludwig angina
Unstable angina
Normal heart sounds
Abnormal heart sounds
Rheumatic heart disease
Heart blocks: Pathology review
Hypoplastic left heart syndrome
Cardiac conduction system
Acyanotic congenital heart defects: Pathology review
Cyanotic congenital heart defects: Pathology review
Post-COVID syndrome: Heart, lungs and clotting
Myocardial infarction
Congenital heart defects: Clinical
MHC class I and MHC class II molecules
T-cell activation
Type III hypersensitivity
Antiphospholipid syndrome
B-cell activation, differentiation, and contraction
Type IV hypersensitivity
Graft-versus-host disease
Antibody classes
Type II hypersensitivity
Integrase and entry inhibitors
Small bowel ischemia and infarction
ACE inhibitors, ARBs and direct renin inhibitors
Cell-mediated immunity of CD4 cells
Cell-mediated immunity of natural killer and CD8 cells
Anaphylaxis
Shock
Hemophilia
Non-steroidal anti-inflammatory drugs
Transplant rejection
Stroke volume, ejection fraction, and cardiac output
Delirium
Dementia and delirium: Clinical
Amnesia, dissociative disorders and delirium: Pathology review
Substance misuse and addiction: Clinical
Typical antipsychotics
Metabolic and respiratory acidosis: Clinical
Dementia with Lewy bodies
Vascular dementia
Abnormal uterine bleeding: Clinical
Bleeding disorders: Clinical
Headaches: Clinical
Post-traumatic stress disorder
Trauma- and stressor-related disorders: Clinical
Clinical Skills: Pulse oximetry
Clinical Skills: BiPAP and CPAP
Anemia: Clinical
Aortic dissections and aneurysms: Pathology review
Aortic aneurysms and dissections: Clinical
Aortic dissection
Cardiac tamponade
Pericardial disease: Pathology review
Coarctation of the aorta
Hypertension
Pneumothorax
Pneumothorax: Clinical
Pleural effusion, pneumothorax, hemothorax and atelectasis: Pathology review
General anesthetics
Emphysema
Pleural effusion: Clinical
Abdominal trauma: Clinical
Glycolysis
Carbohydrates and sugars
Oxygen-hemoglobin dissociation curve
Cellular structure and function
Fatty acid synthesis
Ketone body metabolism
Metabolic acidosis
Disorders of consciousness: Clinical
Hyperkalemia: Clinical
Acid-base disturbances: Pathology review
Plasma anion gap
Diabetes mellitus
Diabetes mellitus: Clinical
Diabetes mellitus: Pathology review
Electrolyte disturbances: Pathology review
Fatty acid oxidation
Alveolar gas equation
Gas exchange in the lungs, blood and tissues
Cardiac muscle histology
Neuromuscular blockers
Long QT syndrome and Torsade de pointes
Opioid agonists, mixed agonist-antagonists and partial agonists
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Bipolar and related disorders
Serotonin and norepinephrine reuptake inhibitors
Seizures and epilepsy
Hypertensive emergency
Hypertensive disorders of pregnancy: Clinical
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
Cardiac work
Cardiac cycle
Cardiac afterload
Cardiac contractility
ECG cardiac hypertrophy and enlargement
Cardiac conduction velocity
Imaging features of COVID-19 (LifeBridge Health)
Altering cardiac and vascular function curves
Action potentials in myocytes
Resting membrane potential
Valvular heart disease: Clinical
Anatomy of the heart
Valvular heart disease: Pathology review
Premature ventricular contraction
Brugada syndrome
Premature atrial contraction
Sleep apnea
Cardiomyopathies: Clinical
Metabolic and respiratory alkalosis: Clinical
Neonatal respiratory distress syndrome
Bronchodilators: Leukotriene antagonists and methylxanthines
Hypokalemia
Hyperkalemia
Newborn management: Clinical
Carbonic anhydrase inhibitors
Regulation of pulmonary blood flow
Baroreceptors
Cranial nerves
Renin-angiotensin-aldosterone system
Anticonvulsants and anxiolytics: Barbiturates
Chronic bronchitis
Bronchiectasis
Brown-Sequard Syndrome
Bacterial epiglottitis
Ectopic pregnancy
Complications during pregnancy: Pathology review
Miscarriage
B-cell development
Placental abruption
Abnormal labor: Clinical
Ischemia
Ascending and descending spinal tracts
Spinal cord disorders: Pathology review
Pyramidal and extrapyramidal tracts
Acute kidney injury: Clinical
Free radicals and cellular injury
DNA damage and repair
Metabolic alkalosis
The role of the kidney in acid-base balance
Psychomotor stimulants
Carbon dioxide transport in blood
Acid-base map and compensatory mechanisms
Pulmonary shunts
Cardiovascular system anatomy and physiology
Pulmonary edema
Sleep disorders: Clinical

Transcript

Watch video only

Antipsychotics, as their name implies, are mainly used to treat schizophrenia and other psychotic conditions. Even though the exact cause of schizophrenia is still unknown, there's some evidence that suggests it’s related to altered levels of the neurotransmitter dopamine. Now, antipsychotics are subdivided into two main categories: the first generation or typical antipsychotics, and the second generation or atypical antipsychotics.

Alright, within the brain, dopamine is found in 4 main dopamine pathways: the mesolimbic pathway, which controls motivation and desire; the mesocortical pathway, which helps regulate emotions; the nigrostriatal pathway, which contains motor neurons that bypass the medullary pyramids, to control involuntary movements and coordination; and lastly, the tuberoinfundibular pathway, which releases dopamine to limit the secretion of prolactin. Other regions of the central nervous system that are rich in dopamine receptors include the chemoreceptor trigger zone, which initiates the vomiting reflex, and the medullary periventricular pathway, which regulates eating behavior.

However, in schizophrenia, altered levels of dopamine mainly affect the mesolimbic pathway and mesocortical pathway. There’s usually high levels of dopamine in the mesolimbic pathway which cause positive symptoms of schizophrenia, such as delusions, hallucinations, and disorganized thought. On the other hand, low levels of dopamine in the mesocortical pathway cause negative symptoms of schizophrenia, such as lack of motivation, social withdrawal, and “flat affect,” which basically means a lack of emotions.

When it comes to treating schizophrenia, some typical antipsychotics like haloperidol, trifluoperazine, and fluphenazine have a higher potency, which means you need less of it to achieve a therapeutic effect. The lower potency antipsychotics include thioridazine and chlorpromazine and they require larger doses to achieve the same therapeutic effect as high-potency antipsychotics.

Now, in conditions such as schizophrenia, typical antipsychotics block dopamine D2 receptors in the mesolimbic pathway, which alleviates positive symptoms of schizophrenia. However, they also block dopamine receptors in the mesocortical pathway, which might actually worsen the negative symptoms.

Other psychiatric indications include psychosis, delirium, bipolar disorder, obsessive-compulsive disorder, Tourette syndrome, and Huntington disease. Aside from their use in psychiatric disorders, blocking dopamine receptors in the chemoreceptor trigger zone can also decrease nausea and vomiting, while blocking histamine H1 receptors can have an antipruritic and sedative effect.

Alright, moving on to side effects. In the tuberoinfundibular pathway, they stimulate the release of prolactin, causing oligomenorrhea, galactorrhea, and gynecomastia; and lastly, in the nigrostriatal pathway, they cause extrapyramidal symptoms, which usually involve abnormal movements.

Let’s start with dystonia, which can occur within a few hours to days of treatment, and includes muscle spasms of the tongue, face, neck, and back. It also causes oculogyric crisis, which is a spasm of the extraocular muscles, causing an upward and outward position of the eyes. After a few days to a month, there could be Akathisia or pseudoparkinsonism. Akathisia is characterized by restlessness and an urge to move the limbs. Pseudoparkinsonism is characterized by muscle rigidity, usually in the facial muscles, giving the face a wooden, mask-like appearance. Other symptoms include bradykinesia, or slow movements, and tremors. It’s important to note that typical antipsychotics are more likely to cause these side effects compared to the atypical antipsychotics. However, extrapyramidal symptoms usually disappear once the medication is stopped.

Now, moving on to tardive dyskinesia, which can present after several months or even years; is characterized by constant involuntary, rhythmic movements. This typically happens with the perioral muscles causing the person to repeatedly smack, or purse their lips. Unlike acute extrapyramidal symptoms, tardive dyskinesia can be irreversible, so the medication should be discontinued at the first sign of tardive dyskinesia.

Key Takeaways

Typical antipsychotics, also known as first-generation antipsychotics, are a class of medications used to treat various psychiatric disorders, particularly schizophrenia and other psychotic disorders. They work by blocking dopamine D2 receptors in the mesolimbic pathway in the brain, which helps to reduce the symptoms of psychosis.

Typical antipsychotics include medications such as chlorpromazine, haloperidol, and fluphenazine. These medications are generally effective at reducing positive symptoms of psychosis, such as hallucinations and delusions, but may have limited effectiveness for negative symptoms and may also cause significant side effects.

Common side effects of typical antipsychotics include extrapyramidal symptoms, such as tremors and muscle rigidity, as well as weight gain, sedation, and sexual dysfunction. Long-term use of these medications may also be associated with a higher risk of developing tardive dyskinesia, a movement disorder characterized by involuntary muscle movements.

Sources

  1. "Katzung & Trevor's Pharmacology Examination and Board Review,12th Edition" McGraw-Hill Education / Medical (2018)
  2. "Rang and Dale's Pharmacology" Elsevier (2019)
  3. "Goodman and Gilman's The Pharmacological Basis of Therapeutics, 13th Edition" McGraw-Hill Education / Medical (2017)
  4. "Neuroleptic Malignant Syndrome" Annals of Pharmacotherapy (2016)
  5. "Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis" The Lancet (2009)
  6. "Update on Typical and Atypical Antipsychotic Drugs" Annual Review of Medicine (2013)